FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Strongbridge Biopharma Surges after being Acquired by Xeris Pharmaceuticals”
Strongbridge Biopharma (NASDAQ: SBBP) surged over 15% in premarket trading after Xeris Pharmaceuticals agreed to acquire the company in a stock and CVR transaction.
The two companies had entered into a definitive agreement under which Xeris will acquire Strongbridge for stock and contingent value rights, creating an innovative leader in Endocrinology and Rare Diseases.
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV® (levoketoconazole), an adrenal steroidogenesis inhibitor with a New Drug Application that is currently under review by the FDA for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation.
For more information, please visit: Strongbridge Biopharma plc
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.